Evidence map›Paper›PMID 38892431›Full record

ArticleInternational journal of molecular sciences2024

Increased Expression of Orexin-A in Patients Affected by Polycystic Kidney Disease.

Ersilia Nigro, Daniela D'Arco, Fiorenzo Moscatelli, Antonio Pisani, Maria Amicone, Eleonora Riccio, Ivana Capuano, Francesca Argentino, Marcellino Monda, Giovanni Messina and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ersilia NigroDipartimento di Scienze e Tecnologie Ambientali, Biologiche, Farmaceutiche, Università della Campania "Luigi Vanvitelli", Via Vivaldi 43, 81100 Caserta, Italy.
Daniela D'ArcoCEINGE-Biotecnologie Avanzate Scarl "Franco Salvatore", Via G. Salvatore 486, 80145 Napoli, Italy.
Fiorenzo MoscatelliDepartment of Human Sciences, Telematic University Pegaso, 80100 Naples, Italy.ORCID 0000-0003-1274-0332
Antonio PisaniUnità di Nefrologia, Dipartimento di Sanità Pubblica, Università di Napoli "Federico II", Via Pansini 5, 80131 Napoli, Italy.
Maria AmiconeUnità di Nefrologia, Dipartimento di Sanità Pubblica, Università di Napoli "Federico II", Via Pansini 5, 80131 Napoli, Italy.ORCID 0000-0001-5082-9499
Eleonora RiccioUnità di Nefrologia, Dipartimento di Sanità Pubblica, Università di Napoli "Federico II", Via Pansini 5, 80131 Napoli, Italy.
Ivana CapuanoUnità di Nefrologia, Dipartimento di Sanità Pubblica, Università di Napoli "Federico II", Via Pansini 5, 80131 Napoli, Italy.
Francesca ArgentinoCEINGE-Biotecnologie Avanzate Scarl "Franco Salvatore", Via G. Salvatore 486, 80145 Napoli, Italy.
Marcellino MondaSezione di Fisiologia Umana e Unità di Dietetica e Medicina dello Sport, Dipartimento di Medicina Sperimentale, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Naples, Italy.ORCID 0000-0002-7184-218X
Giovanni MessinaSezione di Fisiologia Umana e Unità di Dietetica e Medicina dello Sport, Dipartimento di Medicina Sperimentale, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Aurora DanieleCEINGE-Biotecnologie Avanzate Scarl "Franco Salvatore", Via G. Salvatore 486, 80145 Napoli, Italy.
Rita PolitoDepartment of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Orexin-A is a neuropeptide product of the lateral hypothalamus that acts on two receptors, OX1R and OX2R. The orexinergic system is involved in feeding, sleep, and pressure regulation. Recently, orexin-A levels have been found to be negatively correlated with renal function. Here, we analyzed orexin-A levels as well as the incidence of SNPs in the hypocretin neuropeptide precursor (HCRT) and its receptors, HCRTR1 and HCRTR2, in 64 patients affected by autosomal dominant polycystic kidney disease (ADPKD) bearing truncating mutations in the

Indexed as

Orexin ReceptorsOrexinsPolymorphism, Single NucleotideAdultAgedBlood PressureCase-Control StudiesFemaleHumansMaleMiddle AgedPolycystic Kidney, Autosomal DominantPolycystic Kidney DiseasesTRPP Cation ChannelsHCRTR1 protein, humanHCRTR2 protein, humanOrexin ReceptorsOrexinsTRPP Cation Channelsblood pressuremarkerorexin-Apolycystic kidney diseaserenal function

Identifiers

PMID38892431
PMCPMC11172798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.